An analytical review on schizophrenia pharmaceutical treatment along with intelligent retrieval
Keywords:
Schizophrenia, Anti-psychotics, Drug related factors, Intelligent retrievalAbstract
Suicidal thoughts, higher use of resources like hospitalisation and related costs, and clinical deterioration may occur if schizophrenia patients fail to adhere to their drug regimens, according to a new study. We are analysing data from clinical trials of therapy that aim to boost the proportion of patients with schizophrenia who adhere to their medication. Nonadherence to therapy is a problem that affects both patients and healthcare providers. Behavioral treatment, long acting injectables (LAI), and antipsychotics based on methamphetamine LAI technology are a few examples. Only a small number of smartphone applications, such as medicine monitors and voice assistants, have been integrated with AI. The inclusion of clinically relevant samples in randomised, controlled, and blinded studies is necessary to measure not just adherence but also clinically important and long-lasting treatment outcomes for schizophrenia patients.
Downloads
References
Abdel Aziz K, Elamin MH, El-Saadouni NM, El-Gabry DA, Barakat M, Alhayyas F, Moselhy HF. Schizophrenia: impact of psychopathology, faith-healers, and psychoeducation on adherence to medications. Int J Soc Psychiatry. 2016;62(8):719-25. doi: 10.1177/0020764016676215, PMID 27815512.
Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, Starr HL. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554-61. doi: 10.4088/JCP.14m09584, PMID 25938474.
Anderson KH, Ford S, Robson D, et al. An exploratory, randomized controlled trial of adherence therapy for people with schizophrenia. Int J Ment Health Nurs. 2010;19(5):340-9. Arch Psychiatr Nurs 2017;31: 99–110. doi: 10.1111/j.1447-0349.2010. 00681. x, PMID 20887608.
Bain EE, Shafner L, Walling DP, Othman AA, Chuang-Stein C, Hinkle J, Hanina A. Use of a novel artificial intelligence platform on mobile devices to assess dosing compliance in a Phase 2 clinical trial in subjects with schizophrenia. JMIR MHealth UHealth. 2017;5(2): e18. doi: 10.2196/mhealth.7030, PMID 28223265.
Baldessarini RJ. Chemotherapy in psychiatry. 3rd ed ed. New York: Springer Press; 2013.
Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. The Effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients with multi-episode schizophrenia. Schizophr Bull. 2013;39(6):1242-51. doi: 10.1093/schbul/sbt138, PMID 24072808.
Barkhof E, Meijer CJ, de Sonneville LMH, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia: review of the past decade. Eur Psychiatry. 2012;27(1):9-18. doi: 10.1016/j.eurpsy.2011.02.005, PMID 21561742.
Batara, R., Ardani, I. G. A. I., Wardani, I. A. K., Windiani, I. G. A. T., Adnyana, I. G. A. N. S., & Setiawati, Y. (2022). Psychogenic dysphagia in children, and the success of family-based treatment: Case report. International Journal of Health & Medical Sciences, 5(1), 163-168. https://doi.org/10.21744/ijhms.v5n1.1894
Beebe L, Smith KD, Phillips C. A Comparison of telephone and texting interventions for persons with schizophrenia spectrum disorders. Issues Ment Health Nurs. 2014;35(5):323-9. doi: 10.3109/01612840.2013.863412, PMID 24766166.
Beebe LH, Smith K, Phillips C. Effect of a telephone intervention upon self-reported medication adherence and self-efficacy in out-patients with schizophrenia spectrum disorders. Issues Ment Health Nurs. 2016;37(10):708-14. doi: 10.1080/01612840.2016.1214855, PMID 27532874.
Beebe LH, Smith K, Phillips C. Effect of a telephone intervention on measures of psychiatric and nonpsychiatric medication adherence in outpatients with schizophrenia spectrum disorders. J Psychosoc Nurs Ment Health Serv. 2017;55(1):29-36. doi: 10.3928/02793695-20170119-04, PMID 28135389.
Ben-Zeev D, Brenner CJ, Begale M, Duffecy J, Mohr DC, Mueser KT. Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia. Schizophr Bull. 2014;40(6):1244-53. doi: 10.1093/schbul/sbu033, PMID 24609454.
Bickmore TW, Puskar K, Schlenk EA, Pfeifer LM, Sereika SM. Maintaining reality: relational agents for antipsychotic medication adherence. Interact Comput. 2010;22(4):276-88. doi: 10.1016/j.intcom.2010.02.001.
Brain C, Sameby B, Allerby K, Lindström E, Eberhard J, Burns T, Waern M. Twelve months of electronic monitoring (MEMS®) in the Swedish Coast-study: comparison of methods for the measurement of adherence in schizophrenia. Eur Neuropsychopharmacol. 2014;24(2):215-22. doi: 10.1016/j.euroneuro.2013.11.013, PMID 24359935.
Bright CE. Measuring medication adherence in patients with schizophrenia: an integrative review. Arch Psychiatr Nurs. 2017;31(1):99-110. doi: 10.1016/j.apnu.2016.09.003, PMID 28104068.
Çetin N, Aylaz R. The effect of mindfulness-based psychoeducation on insight and medication adherence of schizophrenia patients. Arch Psychiatr Nurs. 2018;32(5):737-44. doi: 10.1016/j.apnu.2018.04.011, PMID 30201202.
Chien WT, Cheung EFC, Mui JHC, Gray R, Ip G. Adherence therapy for schizophrenia: randomized controlled trial. Hong Kong Med J. 2019;25(1); Suppl 2:4-9. PMID 30674700.
Chien WT, Mui J, Gray R, Cheung E. Adherence therapy vs. routine psychiatric care for people with schizophrenia spectrum disorders: randomized controlled trial. BMC Psychiatry. 2016;16(1):42. doi: 10.1186/s12888-016-0744-6.
Chien WT, Mui JH, Cheung EF, Gray R. Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: randomized controlled trial. Trials. 2015;16(1):270. doi: 10.1186/s13063-015-0785-z, PMID 26072311.
Clifford L, Crabb S, Turnbull D, Hahn L, Galletly C. A Qualitative study of medication adherence amongst people with schizophrenia. Arch Psychiatr Nurs. 2020;34(4):194-9. doi: 10.1016/j.apnu.2020.06.002, PMID 32828348.
Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J. Treatment adherence in schizophrenia: patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol. 2015;25(8):1158-66. doi: 10.1016/j.euroneuro.2015.04.003, PMID 26004980.
Dahan S, Behrbalk P, Stolovy T, Greenberger C. Improving adherence in hospitalized patients diagnosed with schizophrenia: an integrative one-on-one intervention. Arch Psychiatr Nurs. 2016;30(6):660-5. doi: 10.1016/j.apnu.2016.03.002, PMID 27888956.
El Khoury AC, Pilon D, Morrison L, Shak N, Llaneza A, Kim E, Lefebvre P. Projecting the long-term economic impact of once-monthly paliperidone palmitate vs. oral atypical antipsychotics in Medicaid patients with schizophrenia. J Manag Care Spec Pharm. 2020;26(2):176-85. doi: 10.18553/jmcp.2020.26.2.176, PMID 32011960.
Ertem MY, Duman ZÇ. Effect of motivational interviews on treatment adherence and insight levels of patients with schizophrenia: randomized controlled study. Perspect Psychiatr Care. 2019;55(1):75-86. doi: 10.1111/ppc.12301, PMID 29888541.
Farooq S, Nazar Z, Irfan M, Akhter J, Gul E, Irfan U, Naeem F. Schizophrenia medication adherence in a resource-poor setting: randomized controlled trial of supervised treatment in out-patients for schizophrenia (STOPS). Br J Psychiatry. 2011;199(6):467-72. doi: 10.1192/bjp.bp.110.085340, PMID 22130748.
Fiorillo A, Barlati S, Bellomo A, Corrivetti G, Nicolò G, Sampogna G, Stanga V, Veltro F, Maina G, Vita A. The Role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review. Ann Gen Psychiatry. 2020 May;19(1):43. doi: 10.1186/s12991-020-00293-4, PMID 32774442.
Fleischhacker WW. Adherence/compliance: a multifaceted challenge. World Psychiatry. 2013;12(3):232-3. doi: 10.1002/wps.20063, PMID 24096784.
Forsman J, Taipale H, Masterman T, Tiihonen J, Tanskanen A. Adherence to psychotropic medication in completed suicide in Sweden 2006-2013: a forensic-toxicological matched case-control study. Eur J Clin Pharmacol. 2019;75(10):1421-30. doi: 10.1007/s00228-019-02707-z, PMID 31218371.
Fowler JC, Cope N, Knights J, Phiri P, Makin A, Peters-Strickland T, Rathod S. Hummingbird Study: protocol for a multicenter exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder, or first-episode psychosis. BMJ Open. 2019;9(6): e025952. doi: 10.1136/bmjopen-2018-025952, PMID 31253613.
Granholm E, Ben-Zeev D, Link PC, Bradshaw KR, Holden JL. Mobile Assessment and Treatment for Schizophrenia (MATS): pilot trial of an interactive text-messaging intervention for medication adherence, socialization, and auditory hallucinations. Schizophr Bull. 2012;38(3):414-25. doi: 10.1093/schbul/sbr155, PMID 22080492.
Gray R, Bressington D, Ivanecka A, Hardy S, Jones M, Schulz M, von Bormann S, White J, Anderson KH, Chien WT. Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):90. doi: 10.1186/s12888-016-0801-1, PMID 27048373.
Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and dec- continuation of long-acting injectable vs. oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127-34. doi: 10.1080/13696998.2017.1379412, PMID 28895758.
Gutiérrez-Casares JR, Cañas F, Rodríguez-Morales A, Hidalgo-Borrajo R, Alonso-Escolano D. Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study. CNS Spectr. 2010;15(5):327-37. doi: 10.1017/s1092852900027553, PMID 20448523.
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-2):9-62. doi: 10.1055/s-0043-116492, PMID 28910830.
Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200-18. doi: 10.1177/2045125312474019, PMID 24167693.
Kane JM, Correll CU. Comments on optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2020; 81:20lr13262a.
Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors, and management strategies. World Psychiatry. 2013;12(3):216-26. doi: 10.1002/wps.20060, PMID 24096780.
Kane JM, Schooler NR, Marcy P, Correll CU, Achtyes ED, Gibbons RD, Robinson DG. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(12):1217-24. doi: 10.1001/jamapsychiatry.2020.2076, PMID 32667636.
Kidd SA, Feldcamp L, Adler A, Kaleis L, Wang W, Vichnevetski K, McKenzie K, Voineskos A. Feasibility and outcomes of a multi-function mobile health approach for the schizophrenia spectrum: app4Independence (A4i). PLOS ONE. 2019;14(7): e0219491. doi: 10.1371/journal.pone.0219491, PMID 31306439.
Kidd SA, Kerman N, Ernest D, Maples N, Arthur C, de Souza S, Kath J, Herman Y, Virdee G, Collins A, Velligan D. A Pilot study of a family cognitive adaptation training guide for individuals with schizophrenia. Psychiatr Rehabil J. 2018;41(2):109-17. doi: 10.1037/prj0000204, PMID 27547853.
Kishimoto T, Hagi K, Nitta M, Leucht S, Olfson M, Kane JM, Correll CU. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018;44(3):603-19. doi: 10.1093/schbul/sbx090, PMID 29868849.
Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957-65. doi: 10.4088/JCP.13r08440, PMID 24229745.
Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU. Long-acting injectable vs. oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192-213. doi: 10.1093/schbul/sbs150, PMID 23256986.
Kopelowicz A, Baker RA, Zhao C, Brewer C, Lawson E, Peters-Strickland T. A multicenter, open-label, pilot study evaluating the functionality of an integrated call center for a digital medicine system to optimize monitoring of adherence to oral aripiprazole in adult patients with serious mental illness. Neuropsychiatr Dis Treat. 2017; 13:2641-51. doi: 10.2147/NDT.S143091, PMID 29089771.
Kreyenbuhl J, Record EJ, Himelhoch S, Charlotte M, Palmer-Bacon J, Dixon LB, Medoff DR, Li L. Development and feasibility testing of a smartphone intervention to improve adherence to antipsychotic medications. Clin Schizophr Relat Psychoses. Winter;12(4):152-67. doi: 10.3371/CSRP.KRRE.070816, PMID 27454213.
Kreyenbuhl J, Record EJ, Palmer-Bacon J. A Review of behavioral tailoring strategies for improving medication adherence in serious mental illness. Dialog Clin Neurosci. Dialogues Clin Neurosci. 2016;18(2):191-201. doi: 10.31887/DCNS.2016.18.2/jkreyenbuhl, PMID 27489459.
Krzystanek M, Krysta K, Skałacka K. Treatment compliance in the long-term paranoid schizophrenia telemedicine study. J Technol Behav Sci. 2017;2(2):84-7. doi: 10.1007/s41347-017-0016-4, PMID 29082310.
Lee Y, Lee MS, Jeong HG, Youn HC, Kim SH. Medication adherence using electronic monitoring in severe psychiatric illness: 4 and 24 weeks after discharge. Clin Psychopharmacol Neurosci. 2019;17(2):288-96. doi: 10.9758/cpn.2019.17.2.288, PMID 30905129.
Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral vs. long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015;21(9):754-68. doi: 10.18553/jmcp.2015.21.9.754, PMID 26308223.
Mohr P, Knytl P, Voráčková V, Bravermanová A, Melicher T. Long-acting injectable antipsychotics for prevention and management of violent behavior in psychotic patients. Int J Clin Pract. 2017;71(9):e12997. doi: 10.1111/ijcp.12997, PMID 28869705.
Montes JM, Maurino J, Diez T, Saiz-Ruiz J. Telephone-based nursing strategy to improve adherence to antipsychotic treatment in schizophrenia: a controlled trial. Int J Psychiatry Clin Pract. 2010;14(4):274-81. doi: 10.3109/13651501.2010.505343, PMID 24917439.
Montes JM, Medina E, Gomez-Beneyto M, Maurino J. A Short Message Service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia. Psychiatry Res. 2012;200(2-3):89-95. doi: 10.1016/j.psychres.2012.07.034, PMID 22901437.
Nielsen J, Jensen SO, Friis RB, Valentin JB, Correll CU. Comparative effectiveness of risperidone long-acting injectable vs. first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull. 2015;41(3):627-36. doi: 10.1093/schbul/sbu128, PMID 25180312.
Ostuzzi G, Mazzi MA, Terlizzi S, Bertolini F, Aguglia A, Bartoli F, Bortolaso P, Callegari C, Caroleo M, Carrà G, Corbo M, D’Agostino A, Gastaldon C, Lucii C, Magliocco F, Martinotti G, Nosé M, Ostinelli EG, Papola D, Piccinelli MP, Piccoli A, Purgato M, Tabacchi T, Turrini G, Ruggeri M, Barbui C, STAR Network Investigators. Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. PLOS ONE. 2018;13(8):e0201371. doi: 10.1371/journal.pone.0201371, PMID 30071042.
Peters-Strickland T, Pestreich L, Hatch A, Rohatagi S, Baker RA, Docherty JP, Markovtsova L, Raja P, Weiden PJ, Walling DP. Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. Neuropsychiatr Dis Treat. 2016; 12:2587-94. doi: 10.2147/NDT.S116029, PMID 27785036.
Phan SV. Medication adherence in patients with schizophrenia. Int J Psychiatry Med. 2016;51(2):211-9. doi: 10.1177/0091217416636601.
Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K. Treatment patterns, health- care resource utilization, and spending in Medicaid beneficiaries initiating second-generation long-acting injectable agents vs. oral atypical antipsychotics. Clin Ther. 2017;39(10):1972-1985.e2. doi: 10.1016/j.clinthera.2017.08.008, PMID 28919292.
Priebe S, Bremner SA, Lauber C, Henderson C, Burns T. Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomized controlled trial. Health Technol Assess. 2016;20(70):1-122. doi: 10.3310/hta20700, PMID 27682868.
Priebe S, Yeeles K, Bremner S, Lauber C, Eldridge S, Ashby D, David AS, O’Connell N, Forrest A, Burns T. Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: a cluster randomized controlled trial. BMJ. 2013;347(October 07-3): f5847. doi: 10.1136/bmj.f5847, PMID 24100934.
Schulz M, Gray R, Spiekermann A, Abderhalden C, Behrens J, Driessen M. Adherence therapy following an acute episode of schizophrenia: a multi-center randomized controlled trial. Schizophr Res. 2013;146(1-3):59-63. doi: 10.1016/j.schres.2013.01.028, PMID 23452506.
Sendt KV, Tracy DK, Bhattacharyya S. A Systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015;225(1-2):14-30. doi: 10.1016/j.psychres.2014.11.002, PMID 25466227.
Shah A, Xie L, Kariburyo F, Zhang Q, Gore M. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable vs. oral antipsychotics. Adv Ther. 2018;35(11):1994-2014. doi: 10.1007/s12325-018-0786-x, PMID 30269292.
Shaner A, Eckman T, Roberts LJ, Fuller T. Feasibility of a skills training approach to reduce substance dependence among individuals with schizophrenia. Psychiatr Serv. 2003;54(9):1287-9. doi: 10.1176/appi.ps.54.9.1287, PMID 12954948.
Song X, El Khoury AC, Brouillette M, Smith D, Joshi K. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. J Med Econ. 2019;22(11):1105-12. doi: 10.1080/13696998.2019.1615927, PMID 31062998.
Staring AB, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengeveld MW, Loonen AJ, Mulder CL. Treatment adherence therapy in people with psychotic disorders: randomized controlled trial. Br J Psychiatry. 2010;197(6):448-55. doi: 10.1192/bjp.bp.110.077289, PMID 21119150.
Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, Marder S, Nuechterlein KH. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: randomized clinical trial. JAMA Psychiatry. 2015;72(8):822-9. doi: 10.1001/jamapsychiatry.2015.0270, PMID 26107752.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938
Suzuki H, Hibino H, Inoue Y, Takaya A. Treatment continuation of 3 second-generation antipsychotic long-acting injections, and Oral paliperidone in patients with schizophrenia for 2 years. J Clin Psychopharmacol. 2018;38(6):649-50. doi: 10.1097/JCP.0000000000000976, PMID 30334868.
Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61-8. doi: 10.1002/wps.20699, PMID 31922669.
Tatu M, Demir S. Effect of group psychoeducation on treatment adherence, quality of life and wellbeing of patients diagnosed with schizophrenia. Issues Ment Health Nurs. 2020; 12:1-11.
Tessier A, Boyer L, Husky M, Baylé F, Llorca PM, Misdrahi D. Medication adherence in schizophrenia: role of insight, therapeutic alliance and perceived trauma associated with psychiatric care. Psychiatry Res. 2017; 257:315-21. doi: 10.1016/j.psychres.2017.07.063, PMID 28800510.
Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Association of antipsychotic polypharmacy vs. monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 2019;76(5):499-507. doi: 10.1001/jamapsychiatry.2018.4320, PMID 30785608.
Titus-Lay EN, Ansara ED, Isaacs AN, Ott CA. Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis. Ment Health Clin. 2018;8(2):56-62. doi: 10.9740/mhc.2018.03.056, PMID 29955546.
Tranulis C, Goff D, Henderson DC, Freudenreich O. Becoming adherent to antipsychotics: a qualitative study of treatment-experienced schizophrenia patients. Psychiatr Serv. 2011;62(8):888-92. doi: 10.1176/ps.62.8.pss6208_0888, PMID 21807827.
Uslu E, Buldukoglu K. Randomized controlled trial of the effects of nursing care based on a telephone intervention for medication adherence in schizophrenia. Perspect Psychiatr Care. 2020;56(1):63-71. doi: 10.1111/ppc.12376, PMID 30912160.
Valenstein M, Kavanagh J, Lee T, Reilly P, Dalack GW, Grabowski J, Smelson D, Ronis DL, Ganoczy D, Woltmann E, Metreger T, Wolschon P, Jensen A, Poddig B, Blow FC. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophr Bull. 2011;37(4):727-36. doi: 10.1093/schbul/sbp121, PMID 19933540.
Velligan D, Mintz J, Maples N, Xueying L, Gajewski S, Carr H, Sierra C. Randomized trial comparing in-person and electronic interventions for improving adherence to oral medications in schizophrenia. Schizophr Bull. 2013;39(5):999-1007. doi: 10.1093/schbul/sbs116, PMID 23086987.
Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, Lam YW, Ereshefsky L, Miller AL. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007;58(9):1187-92. doi: 10.1176/ps.2007.58.9.1187, PMID 17766564.
Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP, Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. The expert consensus guideline series. J Clin Psychiatry. 2009;70; Suppl 4:1-46; quiz 47. PMID 19686636.
Verdoux H, Pambrun E, Tournier M, Bezin J, Pariente A. Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study. Acta Psychiatr Scand. 2017;135(5):429-38. doi: 10.1111/acps.12722, PMID 28332704.
Vincent PD, Demers MF, Doyon-Kemp V, Duchesneau J, Halme A, Masson V. One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada. Schizophr Res. 2017; 185:96-100. doi: 10.1016/j.schres.2017.01.013, PMID 28119036.
von Bormann S, Robson D, Gray R. Adherence therapy following acute exacerbation of schizophrenia: a randomized controlled trial in Thailand. Int J Soc Psychiatry. 2015;61(1):3-9. doi: 10.1177/0020764014529099, PMID 24691494.
Xu DR, Xiao S, He H, Caine ED, Gloyd S, Simoni J, Hughes JP, Nie J, Lin M, He W, Yuan Y, Gong W. Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): a randomized controlled trial. PLOS Med. 2019;16(4): e1002785. doi: 10.1371/journal.pmed.1002785, PMID 31013275.
Yan T, Greene M, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and dec- continuation of aripiprazole-once-monthly 400 mg vs. oral antipsychotics in patients with schizophrenia or bipolar I disorder: a real-world study using US claims data. Adv Ther. 2018;35(10):1612-25. doi: 10.1007/s12325-018-0785-y, PMID 30206822.
Yanagida N, Uchino T, Uchimura N. The effects of psychoeducation on long-term inpatients with schizophrenia and schizoaffective disorder. Kurume Med J. 2017;63(3)(3.4):61-7. doi: 10.2739/kurumemedj.MS00011, PMID 28381728.
Yıldız E, Aylaz R. How counseling based on acceptance and commitment therapy supported with motivational interviewing affects the perceptions of treatment motivation in patients diagnosed with schizophrenia: a qualitative study. J Am Psychiatr Nurs Assoc. 2021;107839032094538. (on-line ahead of print, 29 Jul);27(5):390-404. doi: 10.1177/1078390320945380, PMID 32727253.
Yoshimatsu K, Elser A, Thomas M, Dilley J, Barnes D, Ballinger A, Wozniak S, Mangurian C. Recovery-oriented outcomes associated with long-acting injectable antipsychotics in an urban safety-net population. Community Ment Health J. 2019;55(6):979-82. doi: 10.1007/s10597-019-00412-w, PMID 31102164.
Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treat. 2012; 2012:407171. doi: 10.1155/2012/407171.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
